Kevin Sinfield: Rugby league star to run ultra marathons for MND
The rugby league star aims to run 300 miles (482km) in a week to raise funds for motor neurone disease research. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 26, 2022 Category: Consumer Health News Source Type: news
‘Promising’ new drug shown to slow progression of motor neurone disease – new study
Motor neurone disease is one of the cruellest conditions someone can experience, however, a new study is providing hope to patients. (Source: Daily Express - Health)
Source: Daily Express - Health - September 21, 2022 Category: Consumer Health News Source Type: news
Biogen drug slows progress of motor neurone disease in landmark trial
Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 21, 2022 Category: Pharmaceuticals Source Type: news
ALS: Motor neurone disease breakthrough as drug helps wheelchair-bound sufferer walk again
University of Sheffield researchers found Tofersen, made by Biogen, slowed the progress of motor neurone disease in some patients who previously had no other treatment options. (Source: the Mail online | Health)
Source: the Mail online | Health - September 21, 2022 Category: Consumer Health News Source Type: news
Experimental drug shows signs of slowing motor neurone disease
Biogen drug Tofersen showed promising results when taken for six months beyond previous trialAn experimental drug for motor neurone disease (MND) has shown signs of slowing the progress of the devastating illness in a landmark trial.The results provide fresh hope after a phase-three trial of the same drug had previously failed to make a meaningful difference to patient outcomes after six months of treatment.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 21, 2022 Category: Science Authors: Hannah Devlin Science correspondent Tags: Health Society Motor neurone disease Drugs Science Source Type: news
Eureka science prizes: Justin Yerbury wins research honour for work on motor neurone disease
Biosecurity expert, recycling pioneer and nanomaterials engineer among other Australian scientists recognised with awardsGet ourfree news app,morning email briefing ordaily news podcastA motor neurone disease researcher living with the disease, a nanomaterials engineer and a recycling pioneer were among those awarded Eureka prizes at the Australian Museum on Wednesday night.Established in 1990, the Eureka prizes recognise the work of Australian scientists and science communicators.Sign up to receive an email with the top stories from Guardian Australia every morningContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 31, 2022 Category: Science Authors: Donna Lu Tags: Australia news Science Health Motor neurone disease Recycling Engineering Environment Nanotechnology Coronavirus Waste Infectious diseases Medical research Source Type: news
Epic challenge for MND cyclist who has defied the odds
Davy Zyw did not think he would still be alive four years after being told he has motor neurone disease. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 3, 2022 Category: Consumer Health News Source Type: news
‘It’s like the loss happened yesterday’: how long is too long to mourn?
Losing a loved one can be life-changing and, for some, debilitating. Could a diagnosis help, or are we medicalising a natural human emotion?For a while, Davina Rivers thought something wasn ’t right with her. “It will be seven years in November since my husband died, and I’m still grieving for him every day, I miss him every day, I wish he was here every day,” she says. She has suffered from depression before, and she thought her intense grief had settled, like a grey mist, int o a kind of depression. Rivers and her husband, Eric, married in 1998, and they have three daughters; he died in 2015 at the age of 49. She...
Source: Guardian Unlimited Science - June 16, 2022 Category: Science Authors: Emine Saner Tags: Death and dying Mental health Counselling and therapy Society Psychology & wellbeing Source Type: news
New lifeline for patients as NHS gets £340m fund to provide faster access to latest drugs
The Innovative Medicines Fund (IMF) offers hope to people with rare illnesses and conditions for which there are currently few or no drugs, such as Alzheimer's and Motor Neurone Disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 7, 2022 Category: Consumer Health News Source Type: news
FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Media News - May 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Investor Update - May 31, 2022 Category: Pharmaceuticals Source Type: news
Campaigners blast delays in £50m MND funding
ACTIVISTS have expressed their 'concern' at the Government's reluctance to cut red tape and allow easier access to £50million of funding to help find a cure for motor neurone disease. (Source: Daily Express - Health)
Source: Daily Express - Health - May 1, 2022 Category: Consumer Health News Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Media News - April 29, 2022 Category: Pharmaceuticals Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Investor Update - April 29, 2022 Category: Pharmaceuticals Source Type: news
MND: 'It's like a hand grenade going off in your body'
A man living with motor neurone disease says he tries to stay upbeat despite the "cruel" illness. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 15, 2022 Category: Consumer Health News Source Type: news
